WAS treatment: Stem cell transplant vs gene therapy

The treatment remains donor-dependent and carries clinically relevant risks, including graft-versus-host disease, graft rejection, and mixed donor chimerism.

The comparison usually described as Wiskott–Aldrich syndrome HSCT vs gene therapy is therefore not a simple contest between an established treatment and a newer one. It is a comparison between two different sources of hematopoietic stem cells. HSCT replaces the patient’s hematopoietic system with an allogeneic graft. Lentiviral gene therapy modifies the patient’s own CD34-positive stem cells ex vivo and returns them after conditioning.

Both strategies target the underlying hematopoietic defect. Their risk profiles, laboratory endpoints, donor requirements, and long-term evidence are not equivalent.

The disease creates a narrow therapeutic window

Wiskott–Aldrich syndrome is an X-linked inborn error of immunity caused by pathogenic variants in the WAS gene. The affected protein participates in actin cytoskeleton regulation in hematopoietic cells. Its deficiency produces a characteristic combination of:

• microthrombocytopenia, with reduced platelet count and abnormally small platelets;
• eczema and inflammatory skin disease;
• recurrent bacterial, viral, and fungal infections;
• autoimmune manifestations;
• increased risk of severe bleeding and malignancy.

The phenotype is variable. Some patients present with classic severe WAS. Others have an attenuated phenotype, including X-linked thrombocytopenia or intermittent infection burden. Molecular confirmation is essential because platelet count alone does not establish the diagnosis, and the treatment pathway depends on the clinical phenotype, genotype, age, complications, and availability of a suitable donor.

Without curative hematopoietic reconstitution, severe untreated disease is associated with a life expectancy of under 15 years. Families without a previous diagnosis may receive a molecular diagnosis only after recurrent infections, bleeding, eczema, or unexplained thrombocytopenia have accumulated. The average age of diagnosis in such families has been reported at approximately 24 months.

The diagnostic workflow generally combines:

1. Complete blood count and platelet indices. Microthrombocytopenia is a central biomarker. The platelet volume is diagnostically relevant, not merely the absolute platelet count.

2. Flow cytometry and immunophenotyping. WAS protein expression can support the diagnosis, but normal or residual expression does not exclude a pathogenic variant.

3. Molecular testing. Sequencing of the WAS gene identifies pathogenic variants and clarifies inheritance. A multigene inborn-errors-of-immunity panel may be appropriate when the phenotype is not specific.

4. Functional and clinical correlation. Infection pattern, eczema, bleeding, autoimmunity, and family history determine whether a variant is clinically explanatory.

The treatment decision begins after the molecular and clinical diagnosis has been integrated. It should not be reduced to a single laboratory value.

In WAS, cure is defined by durable hematopoietic correction, not by an isolated improvement in platelet count or infection frequency.

Allogeneic HSCT remains the reference treatment

Allogeneic HSCT uses hematopoietic stem cells from a donor. The graft provides donor-derived hematopoiesis, including immune cells and megakaryocyte-lineage cells. The therapeutic mechanism is therefore direct replacement of the defective hematopoietic compartment.

The strongest HSCT outcomes are associated with a well-matched donor and current transplant protocols. In the available clinical evidence, overall survival can exceed 90% in WAS when a matched donor is used and the patient is treated in an experienced center. This figure is clinically important but incomplete. Survival is not the same endpoint as full immune normalization, stable platelet recovery, absence of autoimmunity, or absence of transplant-related morbidity.

The relevant HSCT variables include:

• donor relationship and HLA compatibility;
• stem-cell source;
• conditioning intensity and composition;
• patient age and pre-existing organ complications;
• active infection at transplantation;
• degree of donor chimerism after graft infusion;
• graft-versus-host disease prophylaxis and monitoring.

Donor matching is a clinical determinant

A matched sibling donor remains a high-value option when available. It provides an allogeneic graft with a favorable immunogenetic relationship and avoids some of the uncertainty associated with alternative donor sources. Matched unrelated donors and other donor categories may also be used, but their risk profile depends on HLA resolution, center experience, conditioning, graft manipulation, and post-transplant management.

The absence of a matched donor does not automatically exclude HSCT. It changes the risk calculation. Alternative donor transplantation may remain clinically appropriate, especially when the disease phenotype is severe or complications are progressing. The decision must be individualized rather than based on the label of the donor category alone.

HSCT endpoints extend beyond survival

A technically successful graft must establish durable donor hematopoiesis. The post-transplant assessment therefore includes serial chimerism analysis, blood counts, lymphocyte subsets, immunoglobulin-related parameters, infection surveillance, and evaluation of autoimmune or inflammatory complications.

Several outcomes require separate interpretation:

• Overall survival: whether the patient remains alive after transplantation.
• Event-free survival: whether survival is maintained without graft failure, major disease recurrence, or severe complications.
• Donor chimerism: the proportion and lineage distribution of donor-derived cells.
• Immune reconstitution: recovery of functional cellular and humoral immunity.
• Platelet recovery: restoration of megakaryocyte and platelet production.
• GvHD burden: acute or chronic graft-versus-host disease and its treatment consequences.

Mixed donor chimerism can be clinically relevant even when the patient is alive and infection frequency has decreased. Lineage-specific chimerism may reveal unequal donor contribution across myeloid and lymphoid compartments. Persistent abnormalities require interpretation within the full clinical and laboratory profile.

Lentiviral gene therapy removes the donor variable

Autologous lentiviral gene therapy uses the patient’s own hematopoietic stem cells. CD34-positive cells are collected, exposed ex vivo to a self-inactivating lentiviral vector carrying functional human WAS complementary DNA, and reinfused after conditioning.

The treatment architecture is different from HSCT in four decisive ways:

• the stem cells are autologous;
• a matched donor is not required;
• the corrected cells must engraft and generate multiple hematopoietic lineages;
• therapeutic output depends on the number and distribution of corrected cells.

Because the graft is autologous, gene therapy does not create the alloreactive donor-recipient interaction responsible for GvHD. Graft-versus-host disease is therefore not a gene therapy complication in the same way it is in allogeneic HSCT.

This does not make gene therapy risk-free. The procedure still involves stem-cell collection, conditioning, cell manufacturing, vector exposure, reinfusion, cytopenic periods, infection management, and long-term molecular surveillance. The relevant safety questions are different from those used for allogeneic transplantation.

Vector copy number is a functional biomarker

The vector copy number, or VCN, measures the average number of vector integrations per transduced cell. It is not a complete measure of treatment quality, but it is a clinically relevant biomarker in WAS gene therapy.

The outcome depends on several linked parameters:

1. The proportion of CD34-positive cells successfully transduced.

2. The VCN in the final cellular product.

3. The ability of corrected cells to engraft after conditioning.

4. The persistence of vector-marked cells over time.

5. The contribution of those cells to lymphoid, myeloid, and megakaryocytic lineages.

6. The functional expression of WAS protein in relevant hematopoietic populations.

Clinical trials of lentiviral gene therapy have demonstrated sustained multilineage vector marking. They have also reported reductions in eczema, infection frequency, bleeding episodes, and disease-related hospitalizations. These are clinically meaningful outcomes because they reflect correction across several disease domains rather than improvement in a single biomarker.

The interpretation must remain assay-specific. VCN measured in the infused product is not identical to VCN measured in peripheral blood months or years later. The laboratory method, sampling time, cellular fraction, and lineage composition affect the result. A single VCN value cannot establish durable clinical correction.

HSCT and gene therapy address different failure modes

The comparison is most useful when separated into distinct clinical and laboratory domains. Treating both interventions as interchangeable makes the analysis less accurate.

The table does not establish a universal first-line treatment. It defines the variables that must be weighted for an individual child.

Immune correction is not identical to platelet correction

WAS gene therapy has produced substantial improvement in immune-related disease manifestations. However, platelet recovery remains a separate technical and biological problem. Platelets are generated from megakaryocytes, and adequate correction of lymphoid or myeloid cells does not automatically guarantee normalized platelet production.

Available evidence indicates that platelet recovery after lentiviral gene therapy correlates strongly with high VCN in transduced CD34-positive cells. Incomplete platelet normalization remains a potential limitation. This is particularly relevant because platelet abnormalities are not a minor laboratory feature of WAS. They contribute directly to bleeding risk and can persist even when eczema and infections improve.

A treatment assessment should therefore report platelet count, platelet size, bleeding history, transfusion requirements, and trajectory over time. The statement that gene therapy corrects WAS is incomplete if it does not specify which disease compartments have been corrected and whether platelet production has reached a physiologically adequate level.

The decisive gene-therapy assay is not vector delivery alone. It is durable, multilineage correction with clinically adequate platelet output.

Clinical selection: donor status is only one variable

The choice between HSCT and gene therapy is determined by a matrix of clinical, molecular, and operational factors. Donor availability is important, but it is not the only determinant.

Factors favoring an allogeneic transplant pathway

HSCT may be strongly favored when:

• a well-matched donor is available;
• the child has a severe WAS phenotype with significant infections, bleeding, or organ complications;
• the transplant center has substantial experience with pediatric primary immunodeficiency;
• the expected benefit of prompt donor-derived hematopoietic reconstitution outweighs the risks of allogeneic transplantation;
• gene-therapy access, manufacturing capacity, or eligibility is limited.

The presence of a matched sibling donor does not make gene therapy irrelevant. It does, however, alter the comparative baseline. Long-term direct comparisons extending beyond two decades are not available, and no universal claim can be made that gene therapy replaces HSCT in every child with a 10/10 matched sibling donor.

Factors supporting consideration of autologous gene therapy

Gene therapy may be clinically attractive when:

• no suitable matched donor is available;
• the risks associated with alternative-donor HSCT are substantial;
• the patient meets the protocol or regulatory criteria for treatment;
• adequate CD34-positive cell collection is feasible;
• manufacturing and quality-control requirements can be met;
• the family and clinical team accept the requirement for prolonged molecular follow-up.

The autologous approach removes donor matching and GvHD from the central risk calculation. It does not remove conditioning toxicity, cytopenias, infection risk during marrow aplasia, or uncertainty regarding the completeness and durability of platelet correction.

Genotype contributes to interpretation but does not replace phenotype

The pathogenic variant can provide information about expected WAS protein expression and disease severity. It does not, by itself, determine the entire treatment decision. The same gene can be associated with phenotypic variation, and laboratory expression does not always predict the full clinical course.

A molecular report should be integrated with:

• platelet morphology and count;
• infection history;
• eczema severity;
• autoimmune disease;
• bleeding phenotype;
• immunoglobulin and lymphocyte data;
• family history;
• prior therapies and complications.

Variant classification also requires discipline. A pathogenic variant in the WAS gene is not equivalent to a forecast of treatment response. Treatment response is assessed through clinical endpoints, engraftment or vector-marking data, immune function, platelet recovery, and long-term surveillance.

Diagnostic and monitoring assays determine the quality of the comparison

The two therapies require different laboratory frameworks. A center that reports only survival or infection reduction is not providing a complete comparative assessment.

Before treatment

Baseline testing should establish the disease phenotype and identify complications that may affect risk. The core dataset generally includes:

• complete blood count with platelet indices;
• lymphocyte subset analysis;
• immunoglobulin assessment;
• infection history and microbiological evaluation where indicated;
• WAS protein expression when informative;
• molecular confirmation of the WAS pathogenic variant;
• HLA typing and donor search for HSCT evaluation;
• organ and infectious-disease assessment before conditioning.

The choice of assay matters. Flow cytometry can be affected by antibody clone, cell type, sample quality, and residual protein expression. Sequencing requires appropriate coverage of the WAS gene and interpretation of variants in the context of laboratory classification standards. A negative limited assay does not exclude a genetic diagnosis if the phenotype remains strongly suggestive.

After HSCT

Post-transplant monitoring emphasizes donor contribution and immune recovery:

• whole-blood and lineage-specific donor chimerism;
• serial blood counts and platelet indices;
• T-cell, B-cell, and natural-killer-cell reconstitution;
• infection surveillance;
• graft-versus-host disease assessment;
• graft failure or rejection evaluation;
• autoimmune and inflammatory monitoring.

The timing of chimerism testing is clinically relevant. Early donor contribution may not predict stable long-term multilineage chimerism. Conversely, a stable overall percentage can conceal a clinically important deficit in a particular lineage.

After gene therapy

Gene-therapy follow-up requires a different panel:

• vector marking in peripheral blood and relevant cell fractions;
• VCN in appropriate cellular populations;
• WAS protein expression;
• platelet count and platelet volume;
• immune-cell subset recovery;
• infection frequency and severity;
• eczema and autoimmune disease activity;
• bleeding episodes and hospitalization burden;
• long-term safety surveillance.

The analytical method must be validated for the intended matrix and detection range. VCN is typically reported as an average value across a cell population. It does not identify which individual cells carry the vector, whether expression is uniform, or whether the corrected cells are functionally dominant in each lineage.

For that reason, VCN should be interpreted with vector marking, WAS protein expression, lineage data, and clinical performance. A high value in the product does not guarantee sustained high marking after engraftment. A lower peripheral-blood value may also require context if the sample contains different proportions of corrected and uncorrected lineages.

Long-term outcomes remain the decisive limitation

Allogeneic HSCT has a larger historical evidence base. Modern matched-donor outcomes support its status as the reference curative treatment for WAS. The residual risks are well characterized in broad terms, although their magnitude varies by donor, conditioning, age, disease status, and center.

Lentiviral gene therapy has demonstrated durable multilineage vector marking and clinically relevant reductions in major WAS manifestations. The evidence supports its role as an effective alternative, particularly when donor matching is unfavorable or unavailable. It does not support a claim of universal equivalence across every endpoint and every patient group.

The unresolved comparison is long-term and population-level. Universal efficacy data extending beyond 20 years for pediatric cohorts treated with lentiviral gene therapy are not yet available. The evidence is also insufficient to state that gene therapy completely replaces allogeneic HSCT for children with a fully matched sibling donor.

Long-term surveillance must therefore retain several independent endpoints:

• survival;
• immune competence;
• severe infection burden;
• bleeding and platelet adequacy;
• autoimmune disease;
• eczema control;
• hospitalization frequency;
• donor chimerism or vector marking;
• VCN trajectory;
• WAS protein expression;
• treatment-related late effects.

A patient can achieve excellent immune reconstitution while retaining a platelet deficit. Another can have adequate platelet recovery but require continued monitoring for immune dysregulation. The clinical utility of either therapy is determined by the combined phenotype, not a single favorable assay.

Rigid assessment of the two treatment pathways

For children with WAS, allogeneic HSCT remains the established curative standard when a suitable matched donor is available. Its principal strengths are mature clinical experience, high survival in optimized settings, and direct donor-derived hematopoietic replacement. Its principal liabilities are donor dependence, GvHD, graft rejection, mixed chimerism, and other allogeneic complications.

Lentiviral gene therapy is an effective autologous alternative. It eliminates the need for a matched donor and avoids GvHD caused by donor-recipient alloreactivity. Clinical trials show sustained multilineage vector marking and improvement in infections, eczema, bleeding, and disease-related hospitalizations. Its principal limitation is variable platelet normalization, which correlates with VCN in transduced CD34-positive cells. Its long-term evidence base remains shorter and less extensive than that of HSCT.

The correct comparison is therefore endpoint-specific:

• Donor availability: gene therapy has a structural advantage.
• GvHD risk: autologous gene therapy has a structural advantage.
• Historical evidence and transplant experience: HSCT has the stronger base.
• Matched-donor survival: HSCT provides highly favorable established outcomes.
• Platelet normalization: neither strategy should be judged without direct platelet and bleeding data; gene therapy requires particular attention to VCN and megakaryocytic correction.
• Long-term certainty: HSCT remains better characterized.
• Molecular monitoring: HSCT relies on donor chimerism; gene therapy relies on vector marking, VCN, and WAS protein expression.

For pediatric WAS treatment, clinical utility is not defined by novelty or by a single survival percentage. It is defined by durable hematopoietic correction, adequate immune function, controlled bleeding, stable platelet production, and an acceptable late-effect profile. Until longer comparative follow-up is available, matched-donor HSCT remains the reference pathway, while lentiviral gene therapy provides a technically credible and clinically important alternative when donor-related constraints materially change the risk-benefit balance.